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Summary
 
Natural killer (NK) receptor signaling can lead to reduced cytotoxicity by NK cells and cy-
tolytic T lymphocytes (CTLs) in vitro. Whether T cells are inhibited in vivo remains un-
known, since peptide antigen–specific CD8
 
1
 
 T cells have so far not been found to express NK
receptors in vivo. Here we demonstrate that melanoma patients may bear tumor-specific CTLs
expressing NK receptors. The lysis of melanoma cells by patient-derived CTLs was inhibited
by the NK receptor CD94/NKG2A. Thus, tumor-specific CTL activity may be decreased
through NK receptor triggering in vivo.
Key words: cytolytic T lymphocytes • natural killer receptors • melanoma • tumor immunity • 
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C
 
ytolytic lymphocytes play a central role in the recog-
nition and elimination of abnormal cells. CD8
 
1
 
 T
cells are well known to efficiently kill virus-infected cells
upon recognition of viral peptides presented by MHC class
I molecules on the surface of infected cells (1, 2). In recent
years, it became clear that CD8
 
1
 
 T cells can also kill tumor
cells through the recognition of tumor cell–derived pep-
tides presented by cell surface MHC class I molecules (3, 4).
Although many experimental treatment protocols to en-
hance tumor immunity have been applied, only a minority
of the treated patients have experienced tumor regression
(5–7). Undoubtedly, the development of more efficient
immune therapy approaches requires a better understand-
ing of tumor immunity. Several biological mechanisms
may account for the failures to achieve efficient immune
protection: on the one hand, the activation of tumor-spe-
cific T cells may be insufficient in intensity and durability
(8) to allow a long-lasting antitumor effect. On the other
hand, tumor cells may develop strategies to evade or even
counteract immune attack, facilitated by the high degree of
genetic instability of advanced tumors. Examples for such
immune evasion strategies are mutations of genes encoding
MHC, tumor antigens, or molecules that regulate antigen
presentation or lymphocyte homing (9–12).
Another mechanism may be the inhibition of cytolytic
function through the recently described NK receptors.
Two families of NK receptor molecules have been identi-
fied. The first are type I transmembrane proteins belonging
to the Ig superfamily, such as p58.2 (13) or Ig-like tran-
script 2 (ILT2)
 
1
 
 (14), and the second are the type II trans-
membrane proteins containing a C-type lectin domain,
such as the heterodimer CD94/NKG2 (15). Upon ligation
with MHC class I recognized on target cells, these NK re-
ceptors may inhibit the cytolytic function. Most of the
known NK receptors have been identified through studies
of NK cells, but subpopulations of CD8
 
1
 
 T cells may also
express them. However, only small proportions (0–10%) of
human CD8
 
1
 
 T cells are positive for a given NK receptor.
Furthermore, the studies showing that NK receptors may
inhibit CTL activity have so far only been done with T cell
lines or clones (16–20). Therefore, it remains questionable
whether NK receptors can significantly inhibit CTLs in
vivo and whether this may concern a physiologically rele-
 
1
 
Abbreviations used in this paper:
 
 ILT2, Ig-like transcript 2; NKT cell, NK
receptor–positive cell expressing CD3 and/or TCR-
 
a
 
/
 
b
 
; TILN, tumor-
infiltrated LN.
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vant proportion of effector CTLs. Thus, further method-
ological progress is required to successfully address this
question experimentally.
Immune protection from melanoma may occur through
CD8
 
1
 
 CTLs that are specific for tumor antigens such as
Melan-A/MART-1 (21, 22). In this study, we investigated
T cells specific for the immunodominant peptide antigen
Melan-A EAAGIGILTV, which is presented by the MHC
class I molecule HLA-A
 
*
 
0201 (22). To investigate pheno-
type and function of human Melan-A–specific T cells, we
took advantage of the novel “tetramer” technology (23–
25). As described previously (25), we generated tetramers
consisting of four HLA-A
 
*
 
0201 molecules, four Melan-A
peptides, and a fluorescent dye. Upon tetramer incubation
and flow cytometry analysis, HLA-A2/Melan-A–specific
lymphocytes were directly visualized without the need for
in vitro expansion. Our study of 10 melanoma patients
shows that tumor antigen–specific T cells may express vari-
ous NK receptors. Furthermore, the lysis of melanoma cells
by patient-derived CTLs was inhibited by the NK receptor
CD94/NKG2A. Together, these findings strongly suggest
that NK receptor triggering may in some instances interfere
with tumor-specific immune responses in vivo.
 
Materials and Methods
 
Blood and LN Samples, Lymphocytes, and Target Cells.
 
Blood
and LNs were obtained from patients with advanced stage malig-
nant melanoma selected on the basis of HLA-A2 antigen expres-
sion. PBLs were separated from heparinized blood by centrifuga-
tion over Ficoll-Paque (Amersham Pharmacia Biotech), washed
three times, and cryopreserved in RPMI 1640, 40% FCS, and
10% DMSO. Vials containing 5–10 
 
3
 
 10
 
6
 
 cells were stored in
liquid nitrogen. LNs collected by surgical dissection were dissoci-
ated to single cell suspensions in sterile RPMI 1640 supple-
mented with 10% FCS, washed, and cryopreserved as indicated
above for PBLs. Aliquots were placed in 24-well tissue culture
plates (Costar Corp.) in 2 ml of IMDM (Life Technologies) sup-
plemented with 0.55 mM Arg, 0.24 mM Asn, 1.5 mM Gln, 10%
pooled human A
 
1
 
 serum, recombinant human (rh)IL-2 (100
U/ml), and rhIL-7 (10 ng/ml). The melanoma cell line Me 290
and the A2/Melan-A–specific CD8
 
1
 
 T cell clone 17 were estab-
lished from surgically excised melanoma metastases from patient
LAU 203 as described (26). The cells were maintained in DME
supplemented with 0.55 mM Arg, 0.24 mM Asn, 1.5 mM Gln,
and 10% FCS.
 
HLA Typing.
 
PBLs were typed for HLA-A2 by flow cytom-
etry using the allele-specific mAb BB7.2 (27). Complete HLA-A
and -B typing was performed by serology, and HLA-A2 allele
typing and HLA-C typing were done by PCR using sequence-
specific oligonucleotides (28). Since all patients were HLA-
A
 
*
 
0201 positive, they all expressed HLA signal peptides able to
bind to HLA-E and to serve as ligands for CD94/NKG2A (29,
30). All six patients shown in Figs. 1 and 2 had at least one of the
known p58.2 binding ligands Cw1, Cw3, Cw7, and Cw8.
In some patients (LAU 181 and LAU 155) both alleles were
p58.2 ligands, while in the other patients there was only one
p58.2 ligand. The Me 290 melanoma cell line and the Melan-
A–specific CD8
 
1
 
 T cell clone 17 were A1, A
 
*
 
0201, B7, B8,
Cw07, Cwx.
 
mAbs.
 
Antibodies specific for the NK receptors p58.2/
CD158b (GL183), CD94 (XA185 and Y9), and the heterodimer
CD94/NKG2A (ZIN199) were provided by A. Moretta, Uni-
versità di Genova, Genova, Italy (31). The ILT2-specific anti-
body HP3F1 (14) was obtained from M. López-Botet, University
Hospital Princesa, Madrid, Spain. Nonlabeled IgG1 and IgG2a
antibodies, and PE-labeled antibodies specific for p58.2 and
CD94 were purchased from Immunotech. mAbs specific for hu-
man CD3, CD8, CD14, CD16, CD28, CD45RA, and TCR-
 
a
 
/
 
b
 
were obtained from Becton Dickinson. All flow cytometry stain-
ings for CD94 were done with the mAb XA185, while Y9 was
used in the cytotoxicity assays. In this study, the term “NKT cell”
was used for all NK receptor–positive cells expressing CD3 and/
or TCR-
 
a
 
/
 
b
 
.
 
Tetramers.
 
Complexes were synthesized as described (24, 25).
In brief, purified HLA heavy chain and 
 
b
 
2-microglobulin were
synthesized by means of a prokaryotic expression system (pET;
R&D Systems, Inc.). The heavy chain was modified by deletion
of the transmembrane cytosolic tail and COOH-terminal addi-
tion of a sequence containing the BirA enzymatic biotinylation
site. Heavy chain, 
 
b
 
2-microglobulin, and peptide were refolded
by dilution. The 45-kD refolded product was isolated by fast pro-
tein liquid chromatography and then biotinylated by BirA (Avid-
ity) in the presence of biotin, adenosine 5
 
9
 
-triphosphate, and
Mg
 
2
 
1
 
 (all from Sigma Chemical Co.). Streptavidin–PE conjugate
(Sigma Chemical Co.) was added in a 1:4 molar ratio, and the
tetrameric product was concentrated to 1 mg/ml. As the anti-
genic peptide, the Melan-A
 
26–35
 
 A27L analogue (ELAGIGILTV)
was used, which has a higher binding stability to HLA-A
 
*
 
0201
and a higher T cell antigenicity and immunogenicity than the
natural Melan-A decapeptide EAAGIGILTV or the nonapeptide
AAGIGILTV (26). In this paper, the abbreviation “tetramer” is
used for the HLA-A
 
*
 
0201/Melan-A
 
26–35
 
 A27L tetramers pro-
duced for this study.
 
Flow Cytometry.
 
LN cells were thawed and cultured for 16–
20 h in IMDM supplemented with 0.55 mM Arg, 0.24 mM Asn,
1.5 mM Gln, 10% pooled human A
 
1
 
 serum, rhIL-2 (100 U/ml),
and rhIL-7 (10 ng/ml). PBLs were thawed and stained after
washing. Cells (0.5–1 
 
3
 
 10
 
6
 
) were stained with tetramers and
FITC-, peridinin chlorophyll protein (PerCP™), and allophyco-
cyanin-labeled mAb conjugates in 50 
 
m
 
l of PBS, 2% BSA, and
0.2% azide for 40 min at 4
 
8
 
C. For indirect fluorescence labeling,
cells were incubated (a) with tetramers, (b) with the primary (NK
receptor–specific) antibody and washed, (c) with sheep anti–
mouse FITC-labeled antibody and washed twice, (d) with IgG1
and IgG2a antibodies, and (e) with PerCP™- and allophycocya-
nin-labeled antibodies. Cells were washed once in the same
buffer and analyzed immediately in a FACSCalibur™ machine
(Becton Dickinson). With this method, the percentages of tet-
ramer-positive cells were slightly lower compared with methods
without multiple wash steps after tetramer incubation (not
shown). Data acquisition and analysis were performed using
CELLQuest™ software. Only cells falling in the “lymphocyte
gate” were analyzed; this gate was defined by forward/side scatter
settings corresponding to a cell population expressing 
 
.
 
98%
CD45 and 
 
,
 
1% CD14 (as determined by control CD45/CD14
stainings).
 
Chromium-release Assay.
 
PBLs were thawed, stained with
HLA-A2/Melan-A tetramers, and sorted using a FACStar™ ma-
chine (Becton Dickinson). The cells were then cultured in
IMDM supplemented with 0.55 mM Arg, 0.24 mM Asn, 1.5 mM
Gln, 10% pooled human A
 
1
 
 serum, rhIL-2 (100 U/ml), and
rhIL-15 (10 ng/ml) starting at day 2 to upregulate CD94/
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NKG2A as described (32). 1 wk later, the cells were again
FACS
 
®
 
 sorted after staining with CD94/NKG2A-specific anti-
bodies and with HLA-A2/Melan-A tetramers. Cytolytic activity
was tested in 
 
51
 
Cr-release assays against the HLA-A
 
*
 
0201–express-
ing melanoma target cell lines Na8 and Me 290 (26). Target cells
were radiolabeled with Na
 
51
 
CrO
 
4
 
 for 1 h at 37
 
8
 
C, 5% CO
 
2
 
, then
washed and coincubated in V-bottomed microwells at the indi-
cated E/T ratio (10
 
3
 
 target cells per well) in the presence of the
IgM mAbs specific for CD94 (or control CD16). After 4 h at
37
 
8
 
C, supernatants were collected and counted in a Top-count™
(Canberra Packard) gamma counter. Percent specific lysis was
calculated as (experimental release 
 
2
 
 spontaneous release) 
 
3
 
100/(total release 
 
2
 
 spontaneous release).
 
Results
 
Tumor Antigen–specific CD8
 
1
 
 T Cells Expressing Inhibitory
NK Receptors.
 
In PBLs, the frequency of CTLs specific
for single MHC/peptide epitopes is usually very low (range
1 in 10
 
4
 
–10
 
6
 
 CD8
 
1
 
 T cells). Their frequency during acute
infections may be much higher (up to 1 in 
 
z
 
10
 
3
 
), but such
high frequencies are not observed for tumor-specific CD8
 
1
 
T cells because immune responses to tumors involve much
lower antigen-specific T cell numbers compared with acute
microbial infections. The frequencies of tumor-specific
CD8
 
1
 
 T cells may be significantly higher in tumor-infil-
trated lymph nodes (TILNs) than in PBLs, since TILNs
may contain up to 3% HLA-A2/Melan-A tetramer–posi-
tive cells among CD8
 
1
 
 cells when analyzed ex vivo (25).
To study the phenotype of tumor-specific CTLs in more
detail, we cultured the TILNs for 2 wk in the presence of
IL-2 and IL-7. This procedure induced expansion of the
tumor antigen–specific T cells, allowing us to perform
multiparameter FACS
 
®
 
 analysis. Fig. 1 shows the results of
TILNs stained with tetramers and antibodies specific for
CD8 and one of four different NK receptors. The TILNs
from the three patients contained high percentages of
CD8
 
1
 
 tetramer-positive cells (1.3–5.1%). In patient LAU
181, these cells were largely negative for the NK receptors
p58.2 and ILT2, but they expressed CD94 and CD94/
NKG2A at high percentages. The Melan-A–specific lym-
phocytes from patient LAU 203 expressed some ILT2 but
only low levels of the other three receptors. Finally, ILT2,
CD94, and CD94/NKG2A were also expressed by some
Melan-A–specific T cells from patient LAU 267. The
Melan-A–specific TILNs from four further patients (data
not shown) expressed no or only low levels (
 
,
 
0.5%) of
NK receptors.
 
In Vivo Identification of Tumor Antigen–specific CD8
 
1
 
 T
Cells Expressing NK Receptors in PBLs from Melanoma Pa-
tients with Vitiligo.
 
It has been demonstrated that mela-
noma patients develop vitiligo more frequently than indi-
viduals without melanoma, and that vitiligo is associated
with an ongoing immune response directed against mela-
noma cells (33, 34). We have recently reported that pa-
tients with vitiligo have high frequencies of Melan-A–spe-
cific circulating CTLs which were detectable ex vivo using
HLA-A2/Melan-A tetramers (24, 34a). The relatively high
percentages of tetramer-positive circulating CTLs provided
us the unique opportunity of investigating NK receptor ex-
pression by specific CTLs in vivo. We obtained PBLs from
three HLA-A2–positive melanoma patients with vitiligo,
and found 0.10–0.17% CD8
 
1
 
 tetramer-positive cells (Fig.
2). These cells expressed the following NK receptors: in
patient LAU 155, practically all tetramer-positive cells were
negative for each of the four NK receptors analyzed (p58.2,
ILT2, CD94, and CD94/NKG2A). In contrast, in patient
LAU 156, most of the tumor antigen–specific CTLs ex-
pressed CD94 and CD94/NKG2A, and about half of them
expressed ILT2. Finally, in the third patient (LAU 269),
there were low percentages of NK receptor–positive, tet-
Figure 1. TILNs may contain Melan-A–specific, NK receptor–positive
CTLs. TILNs obtained from patients LAU 181, LAU 203, and LAU 267
were cultured in the presence of IL-2 and IL-7 for 2 wk and stained with
fluorescent soluble HLA-A*0201/Melan-A26–35 A27L tetramers, anti-
CD8, and antibodies specific for the NK receptors p58.2, ILT2, CD94,
or CD94/NKG2A. Only cells falling in the lymphocyte gate (see Materi-
als and Methods) are shown. In the three dot plots of the top row, the
numbers indicate the percentages of tetramer-positive/CD81 cells. The
dot plots below show the characteristics of lymphocytes in the CD81
gate, and the numbers indicate the percentages of tetramer-positive/NK
receptor–negative or –positive cells among CD81 cells. Background val-
ues obtained using second stage sheep anti–mouse FITC-labeled antibody
alone were ,0.05% (not shown).
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ramer-positive T cells. In conclusion, some tumor antigen–
specific T cells may express NK receptors in vivo, and
there are situations where this is the case for a large fraction
of a given CTL population.
 
T Cells That Express NK Receptors In Vivo Have an Acti-
vated Phenotype.
 
The relatively high frequency of tumor-
specific CTLs in the patients with vitiligo allowed us to in-
vestigate the in vivo phenotype of these cells in more
detail. We investigated the expression of CD45RA, a
marker for naive T cells (35, 36). In PBLs of patients LAU
155 and LAU 269, the tetramer-positive cells expressed
high levels of CD45RA (Fig. 3). In contrast, a reduced
level of CD45RA was found in patient LAU 156, i.e., in
the cells with high levels of NK receptor expression. We
also analyzed the costimulatory molecule CD28 and the
“adhesion” molecule CD57, since downregulation of
CD28 and upregulation of CD57 have been shown to oc-
cur in activated “effector” CTLs (37, 38), and we have re-
 
cently demonstrated that NK receptor expression by T cells
is primarily confined to the CD28
 
2
 
 population (39). Inter-
estingly, the tetramer-positive CD8
 
1
 
 cells of the patient
with high percentages of NK receptor–expressing CTLs
(patient LAU 156) were predominantly CD28
 
2
 
 and CD57
 
1
 
(Fig. 3). In contrast, the tumor-specific CTLs of the other
two patients were mostly CD28
 
1
 
 and CD57
 
2
 
.
 
CD94/NKG2A-mediated Inhibition of Melanoma Cell Lysis.
 
It has been shown that antigen-specific T cell cytotoxicity
can indeed be inhibited through triggering of CD94/
NKG2A (20) or p58.2 (16, 18, 19). However, these results
were obtained with selected T cell lines or clones, leaving
the question open whether NK receptor inhibition is func-
tional in polyclonal T cell responses. Therefore, we investi-
gated the cytotoxicity by tetramer-sorted PBLs. Several of
our attempts failed, since we did not obtain enough tet-
ramer-positive, NK receptor–positive cells through FACS
 
®
 
sorting. However, one of our patients (LAU 156) had ex-
ceptionally high percentages of A2/Melan-A tetramer–pos-
itive, CD94/NKG2A-positive cells in the peripheral blood
(Fig. 2). After FACS
 
®
 
 sorting, the tetramer-positive cells
were cultured for 1 wk and sorted again to obtain pure A2/
Melan-A tetramer CD94/NKG2A double positive CTLs.
These cells were tested in cytotoxicity assays against the
Figure 2. In vivo identification of Melan-A–specific CD81 cells ex-
pressing NK receptors. PBLs from three melanoma patients (LAU 155,
LAU 156, and LAU 269) who had vitiligo were analyzed by multiparam-
eter flow cytometry as described in the legend to Fig. 1. The three dot
plots in the top row show all cells in the lymphocyte gate; the dot plots
below show lymphocytes in the CD81 gate.
Figure 3. NK receptor expression correlating with reduced intensity of
CD45RA and CD28, and upregulation of CD57. PBLs from the three
melanoma patients with vitiligo were analyzed with tetramers and anti-
bodies specific for CD8, CD28, CD45RA, and CD57. The histograms
show the results obtained with CD45RA-specific antibody, for cells gated
for CD81 tetramer-negative (top row) and CD81 tetramer-positive (sec-
ond row) cells. The dot plots show the characteristics of lymphocytes
gated for CD81CD572 (third row) or CD81CD571 (bottom row).
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melanoma cell line Me 290, previously stimulated with
IFN-g for 48 h to increase MHC expression and inhibitory
receptor triggering (40). Indeed, the killing was enhanced
in the presence of blocking anti-CD94 antibody Y9 (Fig.
4, solid line) compared with the killing in the presence of
isotype-matched control anti-CD16 antibody (dashed line).
The target cells were efficiently killed by the NK receptor–
negative CTLs of the patient, and by the HLA-A*0201/
Melan-A–specific CTL clone 17, both to a similar extent in
the presence of anti-CD94 or control antibody. The killing
of the Me 290 melanoma cell line (HLA-A*0201 and
Melan-A positive) was antigen specific, since all of the
CTLs did not lyse the Melan-A–negative melanoma cells
Na8 unless synthetic Melan-A peptide was added (data not
shown). In summary, the data demonstrate that the lysis of
melanoma cells was inhibited due to the inhibitory recep-
tor CD94/NKG2A expressed by the Melan-A–specific ef-
fector CTLs.
Discussion
TILNs of seven melanoma patients were investigated. In
one patient, the Melan-A–specific CD81 T cells were
mostly CD94/NKG2A positive. In other patients, they
were partly ILT2 positive. Similar NK receptor–positive
tumor antigen–specific T cells were also found in periph-
eral blood from at least one melanoma patient with vitiligo.
Furthermore, NK receptor triggering inhibited the cy-
tolytic activity of T cells from one patient. Together, these
results show that CD81 T cells may express NK receptors
in vivo and that this may lead to inhibition of melanoma
cell lysis.
The early observation that NK cells preferentially lyse
target cells that lack MHC class I molecules led to the for-
mulation of the “missing self” hypothesis (41). This sur-
mised that NK cells were endowed with the ability to rec-
ognize and destroy cells lacking expression of MHC class I,
whereas normal cells positive for MHC class I would be
protected from NK cell lysis. Only after the identification
and cloning of several NK receptors could this hypothesis
be confirmed (13–15). It is now established that the bind-
ing of inhibitory NK receptors to MHC class I molecules
on target cells can lead to the delivery of signals that inhibit
the cytolytic function of NK cells. As a consequence, ab-
normal (infected or malignant) cells lacking MHC class I
may be destroyed preferentially.
NK receptors were also found to be expressed by T cells.
However, although NK cells frequently express these re-
ceptors, only small percentages of NK receptor–positive T
cells (NKT cells) were identified (16). In addition, some
NKT cell populations were found to be mono- or oligo-
clonal, as indicated by very limited diversity of T cell re-
ceptor rearrangements (42). Based on these findings, it was
postulated that NKT cells are a small subpopulation and
may represent particular lymphocyte lineages with special
antigen specificity and/or special function.
Recently, Ikeda et al. described a melanoma-specific
CD81 T cell clone that was inhibited by p58.2 recognizing
HLA-Cw7 on autologous melanoma cells (18). Noppen et
al. characterized sister T cell clones bearing the same T cell
receptor specific for a melanoma-associated antigen (20).
Some clones were NK receptor negative, but others
expressed the inhibitory receptor CD94/NKG2A and
showed reduced cytotoxicity to melanoma cells. These re-
sults demonstrated that cloned NKT cells may bear func-
tional T cell receptors specific for classical peptide antigens
presented by MHC class I.
The above-mentioned studies were done with selected
T cell clones that may not be representative, since the ma-
jority of T cell lines and clones are NK receptor negative
(data not shown). To investigate whether NKT cells are
rare or frequent in vivo, we applied the recently developed
tetramer technology which allowed us to visualize and
phenotype peptide antigen–specific, yet polyclonal CD81
T cells without in vitro cultivation. Our data show that tu-
Figure 4. CD94/NKG2A-
mediated inhibition of melanoma
cell lysis by Melan-A–specific
CTLs. PBLs from patient LAU
156 were FACS® sorted to ob-
tain purified HLA-A2/Melan-A
tetramer–positive cells, then in
vitro expanded for 1 wk in the
presence of IL-2 and IL-15. Sub-
sequently, a second FACS® sort-
ing was performed to obtain tet-
ramer-positive cells that were
positive (I) or negative (II) for
CD94/NKG2A (dot plot). These
cells were tested against the
HLA-A*0201–positive melanoma
target cells Me 290 previously
stimulated with IFN-g for 48 h to increase MHC expression. The addition of the blocking mAb Y9 (anti-CD94; solid line) enhanced lysis by the
CD94/NKG2A–positive (I) but not by the negative (II) population. In the former, only low cytolytic activity was observed in the presence of the irrel-
evant isotype-matched control anti-CD16 mAb (dashed line). Lysis by the CD94/NKG2A-negative cells of the patient (II) and by the A2/Melan-A–specific
clone 17 were not altered in the presence of either of the two mAbs. Cultures without mAbs gave similar results as with the anti-CD16 control mAb
(not shown). The results are representative for two experiments.
780 Inhibitory Receptors Expressed by Melanoma-specific T Cells
mor-specific T cells expressing NK receptors can indeed be
found at high percentages in some patients. Thus, NKT
cells may not necessarily represent separate cell lineages, but
can belong to the large pool of T cells with classical pep-
tide/MHC class I specificity.
Why should the CTL activity be modulated through this
pathway? Current evidence suggests that CTLs which are
activated over a prolonged period may need and have in-
hibitory mechanisms, and that human NKT cells may fall
in this category of activated CTLs. Some NK receptor–
expressing T cells have been described to be CD28 negative
and express activation markers such as CD56 (43), CD18,
and CD45RO (42). Using a large panel of different NK re-
ceptor–specific mAbs, we have recently demonstrated that
the majority of NKT cells in the circulation are TCR-a/b1,
CD81, and CD282. Furthermore, these cells account for a
large fraction of CD282 T cells, which make up 10–80%
of circulating CD81 T cells in melanoma patients (39).
CD282 T cells have also been shown to be strongly cyto-
toxic and to proliferate poorly in vitro (37). Thus, T cells
may downregulate CD28 and upregulate NK receptors in
association with prolonged activation for cytolytic effector
function. It is likely that NK receptors are involved in pe-
ripheral regulatory mechanisms avoiding overwhelming
immune responses and immunopathology, particularly in
situations of strong and/or long-lasting immune activation.
The increased numbers of CD282 T cells in prolonged in-
fections such HIV (44) or CMV (45) may support this no-
tion. The function of NK receptors as inhibitory pathways
has the advantage that abnormal infected or tumor cells
lacking MHC class I may still be efficiently eliminated by
the CTLs.
In summary, we found tumor-specific TCR-a/b1CD81
T cells expressing NK receptors that could inhibit the lysis
of melanoma cells. These data strongly suggest that NK re-
ceptors may modulate T cell activities in vivo. NK receptor
expression by T cells varies depending on the cellular acti-
vation status and cytokines such as IL-12, IL-15, and TGF-b
(31, 32, 46). Possibly, new therapeutic strategies modifying
NK receptor expression or function may help improve the
efficacy of immunotherapy in infectious disease, cancer,
autoimmunity, and transplantation.
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